Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 3/20 | 0.31 |
| ▸ | RARG | P13631 | 3/20 | 0.31 |
| ▸ | RARA | P10276 | 2/20 | 0.31 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CRABP2 | P29373 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9007120 | 0.77 | GABRA1 (0.32) | — | |
| SCHEMBL8558172 | 0.74 | RARB (0.40) | RARBRARGRARACYP26A1CYP3A4 | |
| SCHEMBL9006898 | 0.74 | RARA (0.31) | RARBRARGRARA | |
| SCHEMBL9024091 | 0.72 | GABRA1 (0.34) | — | |
| SCHEMBL3300659 | 0.72 | RARB (0.55) | RARBRARGRARACYP26A1CYP3A4 | |
| SCHEMBL9006923 | 0.71 | RARB (0.46) | RARBRARGRARACYP26A1CYP3A4 | |
| SCHEMBL9014691 | 0.71 | GABRA1 (0.35) | — | |
| SCHEMBL1140883 | 0.69 | GABRA1 (0.37) | — | |
| SCHEMBL9842240 | 0.69 | GABRA1 (0.32) | — | |
| SCHEMBL4373673 | 0.69 | RARB (0.58) | RARBRARGRARACYP26A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5346895-A | Treating dermatoses, immunological disorders, wound healing | ALLERGAN, INC. (US) | 1994-09-13 | — | — | US | disclosed |
| WO-1992017471-A1 | CHROMANS AND THIOCHROMANS WITH HETEROARYLETHYNYL SUBSTITUENTS AT THE 7-POSITION HAVING RETINOID-LIKE BIOLOGICAL ACTIVITY | ALLERGAN, INC. (US) | 1992-10-15 | — | — | WO | disclosed |